Prospective randomised comparison of granulocyte colony-stimulating factor (G-CSF) (filgrastim) secondary prophylaxis versus conservative management of chemotherapy-induced neutropenia to maintain dose intensity in chemotherapy for breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN89698860

Enrollment

400

Registered

2002-08-19

Start date

2001-10-03

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Breast

Interventions

Standard iv chemotherapy regimens as per local guidelines. Patients entered into TACT or TANGO protocols, or other protocols of licensed chemotherapies which do not exclude G-CSF usage will be eligi

Eligibility

Inclusion criteria

Inclusion criteria: 1. 18 years or older 2. Histologically confirmed invasive breast cancer 3. No concomitant malignancy 4. No prior chemotherapy (apart from the current regimen) 5. Previous neutropenic event on iv chemotherapy and considered of suitable risk and fitness to continue chemotherapy 6. Written informed consent

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026